IMBdx Inc
461030
Company Profile
Business description
IMBdx Inc detects and analyzes the genomic profile of tumor DNA with a single draw of blood. It provides personalized and optimized analysis information that can be utilized in therapy selection and monitoring. Its AlphaLiquid platform offers ctDNA-based precision diagnostics solutions across the full continuum of cancer care, from therapy selection (AlphaLiquid 100/HRR) to recurrence and minimal residual disease(MRD) monitoring (CancerDetect), and multi-cancer early detection (CancerFind). Its services are Clinical Service BioPharma, Research, and Healthcare Checkup.
Contact
131 Gasandigital 1-ro
21st Floor BYC Highcity Building A
Geumcheon-gu
Seoul08506
KORT: +82 269512906
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
57
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,690.90 | 53.40 | 0.62% |
| CAC 40 | 7,763.84 | 26.64 | 0.34% |
| DAX 40 | 24,091.62 | 160.95 | 0.67% |
| Dow JONES (US) | 42,519.64 | 214.16 | 0.51% |
| FTSE 100 | 8,787.02 | 12.76 | 0.15% |
| HKSE | 23,512.49 | 354.52 | 1.53% |
| NASDAQ | 19,398.96 | 156.34 | 0.81% |
| Nikkei 225 | 37,446.81 | 23.86 | -0.06% |
| NZX 50 Index | 12,371.18 | 43.95 | 0.36% |
| S&P 500 | 5,970.37 | 34.43 | 0.58% |
| S&P/ASX 200 | 8,466.70 | 52.60 | 0.63% |
| SSE Composite Index | 3,361.98 | 14.49 | 0.43% |